CEO and General Counsel of MyoMed Bio, explains how legal strategy—spanning IP, regulatory compliance, and cross-border structuring—is essential for enabling clinical development, managing geopolitical and data protection risks, and aligning biotech operations across China, the U.S., and Australia.
Chinese EV giant BYD investigated in U.S. for alleged ties to Chinese Communist Party; European companies more pessimistic about doing business in China amid economic slowdown; and the world’s first intergovernmental legal organization for mediation established in Hong Kong
Venture capital firm's Chinese investment to be reviewed by U.S. Treasury; Small-scale M&A on the rise despite trade tensions, sluggish growth; and U.S. Congressmen urge delisting of 25 Chinese groups from U.S. exchanges.
CATL and Ant Group’s planned listings could break recent HK IPO records; The lowering of U.S. drug prices will impact Chinese drugmakers; and U.S. House passes sanctions bill targeting trade secret theft by China.
Chinese exporters ship goods through third countries to conceal true origin; China’s stringent cross-border data transfer rules force European pause in funding of scientific research; and Draft revisions of arbitration law aim to increase oversight and international cooperation on arbitration cases
China eases cross-border data transfer restrictions for financial institutions; Trade war prompts plan to open up service sector; and new law firm anti-money laundering regulations to align with international standards
Transfer of data across borders presents a particular compliance challenge for companies in China. Xiangxiang Ma, a partner of Anjie Broad Law Firm, analyses a new document which brings welcome practical clarification to this area
The Cyberspace Administration clarifies its approach to the export of personal and important information out of China; UK weighs whether to include China in foreign influence disclosure rules; and Burberry wins online trademark infringement suit.
